Characterizing novel inhibitors for asthma, allergic rhinitis, and atherosclerosis by quantifying their ability to block pro-inflammatory leukotriene synthesis.
Unlock the Therapeutic Potential of ALOX5: Accelerate Your Inflammation and Cancer Research!
Are you currently facing challenges in elucidating the complex role of Arachidonate 5-Lipoxygenase (ALOX5) in disease pathways, or struggling to develop targeted inhibitors due to a lack of robust enzymatic and binding data? Our ALOX5 Analysis Services leverage state-of-the-art biochemical and biophysical platforms to deliver comprehensive functional characterization and inhibitor profiling. We provide the critical data you need to validate ALOX5 as a therapeutic target and advance your most promising drug candidates with confidence.
Overview of ALOX5 Analysis
Arachidonate 5-Lipoxygenase (ALOX5) is a key enzyme in the biosynthesis of leukotrienes, pivotal mediators in inflammatory and allergic diseases, as well as in certain cancer progression. Precise analysis of its activity, inhibition kinetics, and interaction with regulatory proteins is essential for targeted drug discovery. Our services provide the quantitative rigor required to move from target identification to lead optimization.
| Technical Method | Core Principle | Primary Application in ALOX5 Analysis |
|---|---|---|
| Enzymatic Activity Assays | Spectrophotometric/fluorometric detection of product formation | Determination of enzyme kinetics Km,Vmax and IC50 for inhibitors |
| SPR/MST | Real-time binding kinetics & label-free solution affinity | Measurement of inhibitor binding affinity KD, kon, koff, and mechanism |
| BLI/SPR | Analysis of molecular binding in real-time | Characterization of ALOX5-FLAP complex formation and disruption |
| Cell-Based Assay Systems | Quantification of downstream leukotriene production | Functional validation of inhibitors in physiologically relevant environments |
Fig.1 ALOX5-associated pathways potentially contributing to LGG pathogenesis.1
How Creative Biolabs' Service Can Assist Your Project?
We deliver more than just data points; we provide a complete analytical narrative for your ALOX5-targeted program. Our services clarify the potency, specificity, and mechanism of action of your compounds, de-risking critical decisions in lead selection and optimization. From initial enzyme characterization to complex cellular validation, we equip your team with definitive evidence for preclinical development.
Explore Synergistic Opportunities — Schedule a Strategic Technical Briefing!
Service Workflow
Our streamlined workflow ensures precision and transparency at every stage, transforming your materials into actionable insights.
01Project Initiation & Feasibility Assessment
Provide your ALOX5 protein, small molecule inhibitors, or cell lines expressing relevant pathways.
02Biochemical Characterization
Activity: Determination of baseline ALOX5 enzymatic activity under optimized conditions. Establishment of kinetic parameters (Km for arachidonic acid, Vmax).
03Inhibitor Characterization & Evaluation
Examination of compound collections or key prospects. Calculation of IC50 values and ranking of compound potency.
04Mechanistic & Biophysical Analysis
Measurement of binding affinity (KD), association/dissociation rates (kon/koff) using SPR or MST techniques.
05Cellular Validation & Specificity Testing
Evaluation of inhibitor efficacy in cellular models. Measurement of downstream leukotriene production through ELISA or LC-MS/MS.
06Data Integration & Reporting
Detailed report encompassing all raw and analyzed data, dose-response relationships, kinetic parameters, and strategic insights.
Applications
Inflammatory Disease Drug Discovery
Oncology Research Support
Investigating the role of ALOX5 and its metabolites in cancer cell proliferation and survival.
Mechanism of Action Studies
Elucidating whether candidate therapeutics function via direct ALOX5 inhibition, FLAP antagonism, or dual mechanisms.
Selectivity Profiling
Ensuring lead compounds do not inadvertently inhibit cyclooxygenase pathways.
Biomarker Development Support
Generating precise enzymatic activity data to correlate with disease states.
Published Data
Fig.2 Augmented Alox5 transcriptional profile within the DIC microenvironment.2
A recent study underscored the necessity of integrated ALOX5 analysis. Researchers utilized a combination of enzymatic assays and cellular validation to identify a lead compound. While the compound showed promising IC50 in the biochemical assay, cellular validation revealed reduced potency due to metabolic instability. This critical finding, enabled by a comprehensive analysis workflow, redirected medicinal chemistry efforts toward optimizing pharmacokinetic properties, accelerating the development of a viable clinical candidate.
Why Choose Us?
- End-to-End Expertise: From recombinant protein biochemistry to complex cell-based signaling readouts, we offer a fully integrated suite of assays.
- Orthogonal Validation: We cross-verify key findings using complementary techniques (e.g., IC50 from enzymatic assay + KD from SPR), ensuring unmatched data reliability.
- Physiologically Relevant Models: We specialize in testing inhibitor activity in primary human immune cells, providing data that more accurately predicts in vivo efficacy.
- Proprietary Method Optimization: Our experience allows us to handle challenging oxygen-sensitive reactions and enzyme stability issues.
Harness the Creative Biolabs Advantage – Connect with Us for a Personalized Quote Today.
Frequently Asked Questions
-
Q: What are the key advantages of your ALOX5 enzymatic assay over commercially available kits?
A: Our assays are optimized for sensitivity and scalability. We tailor substrate concentrations and co-factor conditions to match physiological relevance, providing superior data quality over generic kits.
-
Q: Can you help us determine if our inhibitor is targeting ALOX5 directly or interfering with the ALOX5-FLAP interaction?
A: Certainly. We provide specialized assays for protein-protein interactions utilizing BLI or SPR to directly assess the effects of compounds on the ALOX5-FLAP complex.
-
Q: Do you provide support for in vivo pharmacodynamic (PD) studies related to ALOX5 inhibition?
A: We can design and validate ex vivo PD assays and have partnerships to support full in vivo study packages.
-
Q: How much protein or compound is required for a full kinetic characterization study?
A: For a standard KD determination, we typically need microgram quantities of purified ALOX5 and milligram quantities of compound. We excel in optimizing conditions to conserve precious materials.
-
Q: We have a unique cell line model. Can you adapt your cellular assay to our system?
A: Yes, customization is a cornerstone of our service. We collaborate closely to develop tailored cell-based assays using your proprietary cell lines.
Our popular analysis services targeting ALOX5 include but are not limited to the following:
| Cat | Service |
| BAS96-1 | ALOX5 Expression Analysis |
| BAS96-2 | ALOX5 Methylation Analysis |
| BAS96-3 | ALOX5 Knockdown Analysis |
| BAS96-4 | Immune Cell Infiltration Analysis |
| BAS96-5 | ALOX5 Promoter Interaction Analysis |
| BAS96-6 | Drug Sensitivity Analysis |
| BAS96-7 | ALOX5 Polymorphisms Analysis |
Contact Us
Creative Biolabs is your dedicated scientific partner for unlocking the complexities of ALOX5 biology. Our comprehensive analysis services provide the definitive enzymatic, biophysical, and functional data required to validate your target, contact us and optimize your leads, and de-risk your development pathway in inflammation and oncology.
References
- Pan, Rui-han, et al. "Arachidonate lipoxygenases 5 is a novel prognostic biomarker and correlates with high tumor immune infiltration in low-grade glioma." Frontiers in Genetics 14 (2023): 1027690. Distributed under CC BY-SA 4.0, without modification. Doi: https://doi.org/10.3389/fgene.2023.1027690.
- Fang, Wenxi, et al. "Downregulation of Alox5 Inhibits Ferroptosis to Improve Doxorubicin‐Induced Cardiotoxicity via the P53/SLC7A11 Pathway." Journal of Cellular and Molecular Medicine 29.11 (2025): e70641. Distributed under CC BY 4.0, without modification. Doi: https://doi.org/10.1111/jcmm.70641.
For Research Use Only.